Clinical Vice President, Behavioral Health Service Line; Medical Director, Avera McKennan Behavioral Health Center; Medical Director, Avera Marshall Behavioral Health Center
Matthew Stanley, DO, serves as the Vice President of the Behavioral Health Clinical Service Line and as the Medical Director of the Avera McKennan Behavioral Health Center, Sioux Falls, SD and the Avera Marshall Behavioral Health Center, Marshall, MN. He has more than 20 years of experience as a psychiatrist at Avera and is Board Certified by the American Board of Psychiatry and Neurology and by the American Board of Addiction Medicine. He is also a Distinguished Fellow of the American Psychiatric Association. Dr. Stanley is an attending Psychiatrist for Avera McKennan Behavioral Health Services and is an Investigator at the Avera Research Institute. Among his many roles, Dr. Stanley continues to pursue his interest in chemical dependency through training residents in the field and supervising the clinical chemical dependency team at the Avera McKennan Behavioral Health Center. In addition, he is an Assistant Professor for the Department of Psychiatry at the Sanford School of Medicine at the University of South Dakota, Vermillion, SD. He received his doctorate in osteopathic medicine from the University of Osteopathic Medicine and Health Sciences, Des Moines, IA. Dr. Stanley completed his residency at Western Missouri Mental Health Center, Kansas City, MO and at the University of South Dakota in General Psychiatry. Dr. Stanley also has leadership experience, including serving as President of the South Dakota State Psychiatric Medical Association. He is a member of the American Medical Association, American Psychiatric Association, South Dakota Medical Association, South Dakota State Psychiatric Medical Association, American Society of Addiction Medicine and American Academy of Addiction Psychiatry and is a Board Member of the SD Foundation for Medical Care and Tallgrass Recovery Center. He serves as the Chairman of the Avera McKennan Credentials Committee and the Avera System Formulary Committee.
Tuesday, May 1
9:55 AM – 10:10 AM